original ) (raw )Variation in the cost of medications for the treatment of colorectal cancer
Alok Khorana
The American Journal of Managed Care, 2008
View PDFchevron_right
Management of patients with metastatic colorectal cancer: economic consequences of different treatment programs
Mansour Salem
Farmeconomia. Health economics and therapeutic pathways, 2009
View PDFchevron_right
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
Wai Ng
BMC Cancer, 2011
View PDFchevron_right
Medical costs associated with use of systemic therapy in adults with colorectal cancer
Jinma Ren
Journal of managed care pharmacy : JMCP
View PDFchevron_right
Cost minimization analysis of two chemotherapy regimens in the treatment of colorectal cancer in a public reimbursement hospital in Brazil
Marcia Godoy
Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde, 2021
View PDFchevron_right
1234 Is there a relationship between oncology drugs' costs and efficacy?
tatsunori shimoi
European Journal of Cancer, 2015
View PDFchevron_right
The costs of managing patients with advanced colorectal cancer in 10 different European centres
Niels Neymark
European Journal of Cancer, 1999
View PDFchevron_right
Cost of Illness in Colorectal Cancer: An International Review
Christine Kriza
PharmacoEconomics, 2013
View PDFchevron_right
The CAP-CR study: Direct medical costs in Italian metastatic colorectal cancer patients on first-line infusional 5-fluorouracil or oral capecitabine
O. Alabiso
European Journal of Cancer, 2008
View PDFchevron_right
Outpatient cancer drug costs
Jennifer Malin
Cancer, 2002
View PDFchevron_right
Cost issues in sequential therapy
Jonathan Cooke
Journal of Infection, 1998
View PDFchevron_right
Estimating Treatment-Related Costs
Stephanie Earnshaw
Budget-Impact Analysis of Health Care Interventions, 2017
View PDFchevron_right
Costs of treatment of colorectal cancer in different settings in Germany
Axel Grothey
The European Journal of Health Economics, formerly: HEPAC, 2004
View PDFchevron_right
Lifetime and Treatment-Phase Costs Associated With Colorectal Cancer: Evidence from SEER-Medicare Data
Joseph Menzin
Clinical Gastroenterology and Hepatology, 2009
View PDFchevron_right
Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
Enrico Aitini
Cancer Management and Research, 2012
View PDFchevron_right
An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer
Geert Byttebier
Anti-Cancer Drugs, 1999
View PDFchevron_right
Funds Reimbursement of High-Cost Drugs in Gastrointestinal Oncology: An Italian Real Practice 1 Year Experience at the National Cancer Institute of Naples
Maurizio Capuozzo
Frontiers in Public Health
View PDFchevron_right
The cost-effectiveness of different chemotherapy strategies for patients with poor prognosis advanced colorectal cancer (MRC FOCUS)
Andrea Manca , Yolanda Vergel
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2012
View PDFchevron_right
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer
David Kerr
British Journal of Cancer, 2018
View PDFchevron_right
The Cost of Oncology Medicines
Albena Zlatareva
Acta Medica Bulgarica, 2017
View PDFchevron_right
Cost implications of new treatments for advanced colorectal cancer
William Speier
Cancer, 2009
View PDFchevron_right
Improving the management of high cost anticancer drugs in a health care system
Frida Gorreja
Global and regional health technology assessment, 2016
View PDFchevron_right
Cost-effectiveness analysis of treatment of patients with colorectal cancer with FOLFOX4 and XELOX regimens
Jerzy Krysiński
Nowotwory. Journal of Oncology, 2017
View PDFchevron_right
Evolution of costs of cancer drugs in a Portuguese hospital
Antonio Araujo
World journal of clinical oncology, 2014
View PDFchevron_right
No Need to Tax the Sick: Clinical Guidelines for Rofecoxib as an Alternative Effective Method to the Copayment Policy in the Advent of Increasing Pharmaceutical Expenditures
Itamar Grotto
Military Medicine, 2004
View PDFchevron_right
Pharmacoeconomic comparison between chronochemotherapy and FOLFOX regimen in the treatment of patients with metastatic colorectal cancer: a cost-minimization study
Irene Alabiso
Tumori
View PDFchevron_right
The Cost of Systemic Therapy for Metastatic Colorectal Carcinoma in Slovenia: Discrepancy Analysis Between Cost and Reimbursement
Janja Ocvirk
Radiology and Oncology, 2014
View PDFchevron_right
A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation
Fowzia Ibrahim
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2018
View PDFchevron_right
Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada
Caroline Speers
European Journal of Cancer, 2012
View PDFchevron_right
Economic studies in colorectal cancer: challenges in measuring and comparing costs
Laurel Borowski
Journal of the National Cancer Institute. Monographs, 2013
View PDFchevron_right
Long-term costs of colorectal cancer treatment in Spain
Xavier Castells
BMC Health Services Research, 2016
View PDFchevron_right
Cost of cancer care for patients undergoing chemotherapy: The Elements of Cancer Care study
Patricia Bastick
Asia-pacific Journal of Clinical Oncology, 2015
View PDFchevron_right
Does Reimbursement Influence Chemotherapy Treatment For Cancer Patients?
Mireille JACOBSON
Health Affairs, 2006
View PDFchevron_right